Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 1967 |
| INN | Crexavibart, ogalvibart |
| Status | Terminated |
| Drug code(s) | C144-LS, C-135-LS, BMS-986413, BMS-986414 |
| Brand name | None |
| mAb sequence source | mAb - source TBD |
| General Molecular Category | Mixture of 2 |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | SARS-CoV-2 (spike protein) |
| Indications of clinical studies | COVID-19 |
| Primary therapeutic area | Infectious diseases |
| Most advanced stage of development (global) | Terminated at Phase 2/3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | January 11, 2021 |
| Start of Phase 2 | |
| Start of Phase 3 | |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Bristol Myers Squibb |
| Licensee/Partner | Rockefeller University |
| Comments about company or candidate | Not mentioned in BMS Q2 2022 results presentation dated July 27, 2022. Included in NIH's NCT04518410 Phase 2/3 study Feb 2021: Bristol Myers Squibb has secured global rights to a pair of anti-SARS-CoV-2 antibodies discovered by The Rockefeller University. NCT04700163 Phase 1 study started in Jan 2021. |
| Full address of company | New York, United States North America United States of America https://www.bms.com/in |
A combination of two highly neutralizing anti-SARS-CoV-2 mAbs targeting two distinct epitopes on the receptor protein binding domain (RBD) of the SARS-CoV-2 spike protein. LS mutation (M428L/N434S) extends half-life (https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009688)
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |